Reviewer's report
Title:Complete response for advanced liver cancer during sorafenib therapy:
Case Report
Version: 3Date:29 October 2010
Reviewer: Ferry ALM Eskens
Reviewer's report:
Major Compulsory Revisions
Somewhat disappointingly, there still is no single indication of duration of
response, and I cannot imagine that no follow up CT or MRI scans have
meanwhile been performed assessing the CR that likewise has been diagnosed
in mid 2010 (june/july?)
There is also no FU on MMP 9 levels and still no mentioning of 'normal' plasma
levels making it impossible to assess and interpret the changes
I question the paragraph describing the role of sorafenib on portal thrombosis; I
presume there was tumouringrowth and not so much venous thrombosis as such
(because if it were venous thrombosis the patient initially should and could have
been considered for primary resection)
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests'
Reviewer's report
Title:Complete response for advanced liver cancer during sorafenib therapy:
Case Report
Version: 3Date:29 October 2010
Reviewer: Ferry ALM Eskens
Reviewer's report:
Major Compulsory Revisions
Somewhat disappointingly, there still is no single indication of duration of
response, and I cannot imagine that no follow up CT or MRI scans have
meanwhile been performed assessing the CR that likewise has been diagnosed
in mid 2010 (june/july?)
There is also no FU on MMP 9 levels and still no mentioning of 'normal' plasma
levels making it impossible to assess and interpret the changes
I question the paragraph describing the role of sorafenib on portal thrombosis; I
presume there was tumouringrowth and not so much venous thrombosis as such
(because if it were venous thrombosis the patient initially should and could have
been considered for primary resection)
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests'
Please review this paper.
user
Reviewer's report
Title:Complete response for advanced liver cancer during sorafenib therapy:
Case Report
Version: 3Date:29 October 2010
Reviewer: Ferry ALM Eskens
Reviewer's report:
Major Compulsory Revisions
Somewhat disappointingly, there still is no single indication of duration of
response, and I cannot imagine that no follow up CT or MRI scans have
meanwhile been performed assessing the CR that likewise has been diagnosed
in mid 2010 (june/july?)
There is also no FU on MMP 9 levels and still no mentioning of 'normal' plasma
levels making it impossible to assess and interpret the changes
I question the paragraph describing the role of sorafenib on portal thrombosis; I
presume there was tumouringrowth and not so much venous thrombosis as such
(because if it were venous thrombosis the patient initially should and could have
been considered for primary resection)
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests'
assistant